Title of Invention

BODY FLUID TREATING FILTER DEVICE

Abstract A body fluid treating filter device capable of maintaining its treating pressure within a clinically safe pressure range even if body fluid treatment is performed over a long period and having excellent property for recovering a body fluid after the body fluid treatment is completed. A body fluid treating cylindrical filter layer is stores in a cylindrical container having two body fluid flow ports. The cylindrical filter layer is disposed so that the inner space of a container can be divided into two parts by making its both end parts fluid-tight and fixing at least one of these both end parts to the inner wall surface of the container. One of the inner spaces of the container divided by the cylindrical filter layer is allowed to communicate with the first body fluid flow port and the other of the inner spaces of the container divided by the cylindrical filter layer is allowed to communicate with the second body fluid flow port. The body fluid treating cylindrical filter device is characterized in that a bar-like flow passage resistant member extending along the center axis is installed in the hollow part of the cylindrical filter layer, and a spacer layer for flowing the body fluid of 0.7 to 3.5 mm in thickness is formed between the outer peripheral surface of the cylindrical filter layer and the container and between the inner peripheral surface of the cylindrical filter layer and the flow passage resistance member.
Full Text DESCRIPTION
BODY FLUID TREATING FILTER DEVICE
TECHNICAL FIELD
The present invention relates to a body fluid-treating filter device packed with a
body fluid-treating filter material for effectively removing specific components from a
large amount of body fluid such as blood, plasma, and lymph fluid. The present
invention further relates to a body fluid-treating filter device packed with a body
fluid-treating filter material for changing the functions of components contained in a
large amount of body fluid such as blood, plasma, and lymph fluid.
BACKGROUND ART
In recent years, there is an increasing demand for technologies for removing
specific proteins, leukocytes, toxins, and the like contained in body fluids of patients to
be applied to an extracorporeal circulation blood purification therapy of curing
autoimmune diseases, such as systemic lupus erythematosus, chronic or malignant
articular rheumatism, multiple sclerosis, chronic ulcerative colitis, and Crohn's disease,
as well as other diseases such as sepsis, inflammatory bowel disease, leukemia, and
cancer, or for immunity control before an organ transplant operation.
High reliability to safety as a medical device apparatus, not to mention high
removing capability of the materials to be removed, is required for a body fluid-treating
filter device used in these applications. For example, as a leukocyte-removing filter
apparatus well known as an example of the above filter apparatus, a flat-type filter
device in which nonwoven fabric made from ultra-thin fibers or a filter device equipped
with a housing packed with a filter material wound in a cylindrical form (for example,
Patent Document 1) are widely used.
1

A structure of a body fluid-treating filter device will be outlined. Figures 6 and
7 show commonly used typical flat-type or cylindrical-type body fluid-treating filter
devices. In the figures, a body fluid-treating filter layer 12 formed in the form of a flat
plate or a cylinder is housed in a housing 11.
In the cylindrical body fluid-treating filter device of Figure 7, one end of the
filter layer 12 is completely sealed with a dish 16, the other end of the filter layer 12 is
liquid-tightly secured to the inside of the lid 18, which has a body fluid flow port 52,
and the hollow section 20 of the filter layer 12 communicates to the outside of the
device.
If the body fluid to be treated is introduced in this structure from the body fluid
flow port 51 (in this case, a body fluid inlet port), the body fluid flows through the filter
layer 12 and is sent to the outside from the body fluid flow port 52 (in this case, a body
fluid outlet port), while filling the void between the inner wall of the housing 11 and the
surface of the filter layer 12. Arrows in the Figures indicate the directions in which the
body fluid flows.
In some cases, the device may be operated by causing the body fluid to flow in
the directions opposite to the direction of the arrows. In these embodiments, if the
body fluid is introduced from the body fluid flow port 52 (in this case, a body fluid inlet
port), the body fluid flows through the filter layer 12 and is sent to the outside from the
body fluid flow port 51 (in this case, a body fluid outlet port), while filling the void
between the inner wall of the housing 11 and the surface of the filter layer 12.
When such a body fluid-treating filter device is actually used, the pressure in the
device increases in some cases depending on the state of the blood to be treated, for
example, when the amount of a blood anticoagulant added is insufficient or the blood
anticoagulant is mixed only insufficiently. In other cases, when a physiological
solution is caused to flow in order to recover the blood from the filter device, the
physiological solution does not necessarily flow through the entire filter device,
2

resulting in insufficient recovery of the body fluid. In particular, in the flat-type body
fluid-treating filter device of Figure 6, there was a problem of uneven flow of the body
fluid introduced from the body fluid flow port 51, since such a body fluid flows through
the void between the inner wall of the housing 11 and the surface of the filter layer 12,
while spreading two dimensionally.
In addition, a filter device containing a body fluid-treating filter material
cylindrically wound around a core pipe having a porous section has been disclosed
(Patent Document 2). Although this filter device has an effect of efficiently filling a
body fluid-treating filter in a housing, countermeasures against the pressure increase
and blood poor recovery were still insufficient since the essential structure remained the
same as above.
As mentioned above, commonly used fluid-treating filter devices have problems
besides basic performance that should be still improved as a medical apparatus.
[Patent Document 1] JP-A-62-243561
[Patent Document 2] JP-A-9-239022
DISCLOSURE OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
In view of these problems in commonly used technologies, an object of the
present invention is to provide a body fluid-treating filter device which can maintain the
treating pressure of the filter device in a clinically safe range during operation for a long
period of time and can exhibit excellent body fluid recovery performance after
completion of a body fluid treatment.
Means for Solving the Problems
As a result of extensive studies with an objective of solving the above problems,
the present inventors have found that it is important to appropriately control the flow
distribution of a fluid in a body fluid-treating filter device. Specifically, the inventors
3

have found that the flow distribution of a fluid inside the device can be improved by
causing the body fluid to be treated to extensively flow from near the end of a plate-like
or cylindrical filter having an end surface and disposing a specific spacer layer in
several gaps in the body fluid-treating filter device, whereby the problems in
generally-used technologies can be totally solved. This finding has led to the
completion of the present invention.
Accordingly, the present invention provides:
(1) A cylindrical body fluid-treating filter device comprising a cylindrical housing
which has two body fluid flow ports and a body fluid-treating cylindrical filter layer
housed in the cylindrical housing, the cylindrical filter layer being disposed so as to
divide the inner space of the housing into two hollow sections by liquid-tightly sealing
the both ends and securing at least one end thereof to the inner wall of the housing, one
of the hollow sections of the housing divided by the cylindrical filter layer
communicating with the first body fluid flow port, and the other hollow section in the
housing divided by the cylindrical filter layer communicating with the second body
fluid flow port, wherein a rod-shaped flow passage resistant member extends through
the hollow section along the center axis formed by the cylindrical filter layer, and a
spacer layer for allowing a body fluid to flow with a thickness of not less than 0.7 mm,
but not more than 3.5 mm, is provided between the outer circumference of the
cylindrical filter layer and the housing, and between the inner peripheral surface of the
cylindrical filter layer and the flow passage resistant member.
(2) The cylindrical body fluid-treating filter device according to (1) above, wherein
the spacer layer for flowing a body fluid with a thickness of not less than 0.7 mm, but
not more than 3.5 mm, provided between the inner peripheral surface of the
cylindrical filter layer and the flow passage resistant member extends 1/4 to 15/16 of the
length of the hollow section from one end of the cylindrical filter layer.
(3) The cylindrical body fluid-treating filter device according to (1) or (2) above,
4

wherein the flow passage resistant member has a shape of which the cross-sectional area
is fixed on the side near the end of the cylindrical filter layer, but continuously or
intermittently decreases toward the other end.
EFFECT OF THE INVENTION
The body fluid-treating filter device of the present invention can maintain the
treating pressure of the filter device in a clinically safe range during operation for a long
period of time and can exhibit excellent body fluid recovery performance, leaving only
a small amount of reside in the device after completion of a body fluid treatment.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic front cross-sectional view of one example of a plate-like
body fluid-treating filter device according to the present invention.
Figure 2 is a schematic front cross-sectional view of one example of a
cylindrical body fluid-treating filter device according to the present invention.
Figure 3 is a cross-sectional view along the A-A line of one example of a
cylindrical body fluid-treating filter device according to the present invention.
Figure 4 is a cross-sectional view along the B-B line of one example of a
cylindrical body fluid-treating filter device according to the present invention.
Figure 5 is a schematic front cross-sectional view of one example of a body
fluid-treating filter device according to the present invention, in which the
cross-sectional area of a flow passage resistant member changes.
Figure 6 is a schematic diagram showing a front cross-sectional view of a
commonly-used plate-like body fluid-treating unit.
Figure 7 is a schematic diagram showing a flow of a body fluid when a flow
passage resistant member is not provided in a commonly-used cylindrical body
fluid-treating unit.
5

Figure 8 is a schematic diagram showing a flow of a body fluid when a flow
passage resistant member is provided in the cylindrical body fluid-treating device of the
present invention.
Figure 9 is a schematic diagram showing a cylinder (a cylindrical housing).
EXPLANATION OF SYMBOLS
10: Spacer layer
11: Housing of a filter layer
12: Body fluid-treating filter layer
13: Outer spacer layer
14: Inner spacer layer
15: Flow passage resistant member
16: Dish (one end)
17. Lid having body fluid flow port
18. Lid having body fluid flow port
19: Sealing cap
20: Hollow section
51: Body fluid flow port (inlet port)
52: Body fluid flow port (outlet port)
BEST MODE FOR CARRYING OUT THE INVENTION
The body fluid-treating filter device of the present invention is a device having a
body fluid-treating filter material which is liquid-tightly housed in a housing equipped
with body fluid flow ports used as an inlet port and an outlet port of a body fluid. It is
used as a filter or an adsorber of a body fluid such as blood, plasma, and lymph fluid.
There is a body fluid-treating filter device for returning body fluid components which
have deteriorated due to various diseases into a normal state, a body fluid-treating filter
6

device for changing the immunity capability of a biological entity, and the like.
For example, a blood cell/plasma separator for filtering plasma containing malignant
substances such as self-antibodies and immune complex, which is used for a collagen
disease, an autoimmune disease, and the like, a filter for selectively removing high
molecular weight material which contain malignant substances from plasma, an
adsorber for selectively adsorbing malignant substances from plasma, an adsorber for
adsorbing poisonous substances from the blood of a drug-poisoned patient, an adsorber
for adsorbing bilirubin from the blood of a liver disease patient, an adsorber for
adsorbing a blood-type substance from blood of a blood-type incompatibility pregnancy
patient, a blood separation filter for removing leukocytes and lymphocytes from the
blood of an autoimmune disease patient, a blood cell separation filter for removing
leukemia cells from the blood of a leukemia patient, a cell-stimulating device for
stimulating immunocompetent cells in blood to induce a specific function, and the like
can be given as examples of the body fluid-treating filter device.
Figure 1 is a cross-sectional view showing a typical structure. As previously
described referring to Figure 6 in the chapter of the Background Art, a body
fluid-treating filter layer 12 formed in the shape of a plate is housed in a housing 11, and
a spacer layer 10 with a gap of 0.7 to 3.5 mm from the internal circumference of the
housing is provided on both sides of the body fluid-treating filter layer 12. The body
fluid to be treated is introduced from a body fluid flow port 51 into the spacer layer
through the entire end face of the body fluid-treating filter layer. The body fluid
passing through the body fluid-treating filter layer flows to a spacer layer on the
opposite side, and is discharged out of the housing from a body fluid flow port through
the other entire end face of a body fluid-treating filter layer.
According to the present invention, a body fluid flows in from the entire end
face of the filter layer and passes through the above-mentioned specific spacer layer,
whereby, differing from the commonly-used technique shown in Figure 6, the body
7

fluid flows almost uniformly at a certain flow rate on the surface of the filter layer in
one direction. In this manner, an uneven flow in the filter layer can be prevented.
Moreover, since it is possible to cause a body fluid to flow to the end of the filter by
appropriately selecting the thickness of the filter layer, a short pass of the filter layer can
be prevented and, consequently, the pressure loss of the device can be reduced. This
ensures a long life of the device and reduces the amount of residual blood during a
washing operation.
If the thickness of the spacer layer is less than 0.7 mm, the pressure loss of the
body fluid flowing through the spacer layer increases. Not only it is difficult to
maintain a uniform flow through the filter layer, but also a rapid increase in the pressure
rise in the entire device occurs. On the other hand, if the thickness is more than 3.5
mm, although a uniform flow of a body fluid through the entire filter layer can be
ensured and the pressure loss in the entire device can be reduced, the body fluid cannot
flow smoothly in some parts of the device due to an increase in the volume of the spacer
layer. In addition, the amount of residual blood during washing increases.
It is possible to intentionally reduce the amount of a body fluid filtered near the
end of the filter by increasing the thickness of the spacer layer near the end as shown in
Figure 1, whereby the amount of residual blood during washing can be decreased.
The area with an increased thickness is preferably about 1/16 to 3/4 of the length
of the filter layer in the direction of the body fluid.
Figure 2 is a cross-sectional diagram showing a typical structure of a cylindrical
body fluid-treating filter device. In Figure 2, a body fluid-treating filter layer formed
in a cylindrical shape is installed inside a cylindrical housing 11, and one end of the
filter layer 12 is completely sealed with a dish 16. The other end of the filter layer 12
liquid-tightly secured to the inside of a lid 18 which has a body fluid flow port 52, and a
hollow section 20 of the filter layer 12 communicates to the outside of the device. In
the same manner as in the device shown in Figure 7, the body fluid to be treated flows
8

either in the direction from the body fluid flow port 51 (the body fluid inlet port) to the
body fluid flow port 52 (the body fluid outlet port) or in the opposite direction.
The body fluid-treating filter layer used in the present invention is formed from
a filter material which can remove specific blood cells, proteins, toxins, and the like
from a body fluid such as blood. Such a filter material is preferably a material which
can selectively entrap the blood cells, proteins, toxins, and the like to be removed.
The filter layer may be made from a material which can entrap or adsorb the
object to be removed by utilizing the physical and chemical properties of the material
itself, or a material containing a ligand having selective affinity with the object to be
removed immobilized thereon. Of course, a filter layer material having these
properties in combination can be used. A specific filter layer material can be
appropriately selected according to the object to be removed. In order to improve
selectivity of the object to be removed, a material whereof the surface has been
modified by polymer coating, grafting, or immobilization of a ligand as disclosed in
JP-B-6-51060 is preferably used.
As a form of the filter layer, a plate-like or a hollow cylindrical formed material
made from a sheet-like bag packed with particles or sheets of nonwoven fabric, woven
fabric, or a porous material can be given. When leukocytes are removed, the use of
nonwoven fabric, woven fabric, or a porous material as a filter material is preferable
from the viewpoint of removal efficiency. As the fiber material used for the nonwoven
fabric or woven fabric, synthetic fiber, inorganic fiber, and the like can be used.
Among these, polyesters such as polyethylene terephthalate and polybutylene
terephthalate, nylon, polyolefins such as polypropylene and polyethylene, a polystyrene
resin, and synthetic fiber such as polyacrylonitrile are preferably used.
The filter layer may be a plate-like or hollow cylindrically-formed article made
from either a single filter material or a combination of two or more filter materials.
When a combination of two or more types of nonwoven or woven fabric is used, use of
9

filter materials with different average fiber diameters or different filling densities is
effective in order to increase the removal performance and removal speed. Also, in the
case of a sheet of a porous material, it is preferable to combine sheets with different
average pore sizes. In addition, a nonwoven fabric, a porous material sheet, particles
formed into a sheet, and the like may be combined.
The housing 11 of the present invention consists of two or more parts to house
the filter layer therein. In the plate-like body fluid-treating filter device shown in
Figure 1, the housing 11 is a casing dividable into two or more parts, each having a
body fluid flow pipe. In the cylindrical body fluid-treating filter device shown in
Figure 2, the housing 11 has a cylinder for housing the filter layer 12, a lid 17 having a
body fluid flow port 51 and a lid 18 having a body fluid flow port 52, each covering the
ends of the cylinder, and a pair of sealing caps 19 which liquid-tightly secures the lid 17
and lid 18 to the cylinder. It should be understood that these are typical structures and
that the housing structure is not limited to these insofar as the same flow of the body
fluid as in the body fluid-treating filter device of the present invention can be ensured.
There are no particular limitations to the material used for the housing of the present
invention. General purpose resins such as polycarbonate, polysulfone, polypropylene,
nylon 6, nylon 12, polyethylene terephthalate, polyethylene, and Teflon(trade mark) can
be suitably used.
The body fluid-treating device of the present invention is characterized by being
provided with spacer layers 10,13, and 14 having a thickness of 0.7 to 3.5 mm, on both
filtration surfaces of the body fluid filter layer 12. The spacer layer as used in the
present invention refers to a space between the housing wall and the outer surface of the
body fluid-treating filter layer, and a layer which controls the flow of a treated fluid in
the space formed by the body fluid-treating filter layer. In the case of a cylindrical
filter, the spacer layer refers to the space formed by the innermost cylindrical filter layer
or the space between the innermost cylindrical filter layer and the flow passage
10

resistant member.
In the case of a cylinder-type body fluid-treating device, the hollow section of a
cylindrical filter layer can be the spacer layer 14 of the present invention, if the diameter
is more than twice the thickness of the usual spacer layer, that is, if the diameter is
between 1.4 mm and 7.0 mm. When the diameter of the hollow section is more than
7.0 mm, a spacer layer with a thickness 0.7 to 3.5 mm, as a gap between the outer
surface of the flow passage resistant member and the inner surface of the filter layer,
can be formed by providing a flow passage resistant member 15 in the hollow section
20 of filter layer 12, as shown in Figure 2, Figure 5, and Figure 8.
The flow passage resistant member 15 in the present invention refers to a
component provided in the hollow section 20 on the inner peripheral surface of the body
fluid-treating filter layer 12, extending from one end 16 of the filter layer 12 on the side
of the body fluid flow port 51 in the direction of the body fluid flow port 52
communicating with the hollow section 20. The flow passage resistant member 15
creates a pressure loss in the flow passage by narrowing the cross-sectional area of the
hollow section.
Any material such as a rod-shaped article that can resist flow of a fluid in the
hollow section can be used as the flow passage resistant member 15. A solid rod, a
hollow rod, a porous body, and the like can be given as specific examples. A solid rod
or a hollow rod is preferable from the viewpoint of ease of handling. Any material that
can be suitably used as a medical application component can be used for the flow
passage resistant member. The same material as that of the housing may be used.
The flow passage resistant member may have a shape with a fixed cross-section
lengthwise or a shape tapering, partly or through the entire length, toward the body fluid
flow port 52 communicating with the hollow section. A shape of which the
cross-section conically tapers toward the body fluid flow port 52 leading to the hollow
section, in particular, a shape of which the cross-section does not change or changes
11

only slightly in the area near the body fluid flow port 51 communicating with the outer
surface of the filter material, is preferably used. One example of such a shape is
shown in Figure 5.
The length of the flow passage resistant member is preferably such that the
length of the part in which the gap between the flow passage resistant member and the
filter layer inner surface is 0.7 to 3.5 mm toward the body fluid flow port 52
communicating with the hollow section, fluid-treating filter layer is from 1/4 to 15/16,
and particularly 3/4, of the length of the hollow section. If the length is less than 1/4, it
is difficult to obtain a uniform flow of a body fluid and the amount of residual body
fluid left in the device in the recovery operation using a physiological solution tends to
increase. If it is more than 15/16, the fluid passage resistance increases and the body
fluid-treating filter device tends to become easily clogged. A more preferable range is
1/4 to 3/4, and it is still more preferably 3/10 to 13/20, and particularly preferably 7/20
to 11/20.
The spacer layer may be any layer which can form and maintain a certain gap in
the above-mentioned space, specifically, a space in the shape of a layer formed by a
spacer material such as a mesh sheet or a porous sheet. On the other hand, a spacer
material may be provided by producing irregularities on the wall of a cylindrical
housing or on the outer surface of the flow passage resistant member, or by disposing a
material equivalent to the irregularities. A mesh sheet is preferable from the viewpoint
of ease of handling and protecting the outer surface of the body fluid-treating filter
material.
To ensure easy flow in the spacer layer, the product of the air permeability and
the thickness of the spacer material is preferably 50 times or more, and more preferably
100 times or more the product of the air permeability and the thickness of the filter
material in the case of a sheet-like spacer material. If the product of the air
permeability and the thickness of the spacer material satisfies this condition, the spacer
12

material may be the same material as the body fluid-treating filter material (for example,
nonwoven fabrics with a different specification). A product produced by stacking
these materials is preferable for ensuring a uniform flow of a body fluid.
When the body fluid-treating filter material is formed from two or more filter
layers with different specifications and the outermost circumference of the filter
material is directly in contact with the inner surface of the housing, the outermost layer
is regarded as a spacer layer to the extent that the product of the air permeability and the
thickness of the outermost filter layer is 50 times or more the product of the air
permeability and the thickness of the inner filter layer. On the other hand, when the
innermost circumference is directly in contact with the surface of the flow passage
resistant member, the innermost layer is regarded as the spacer layer to the extent that
the product of the air permeability and the thickness of the innermost filter layer is 50
times or more the product of the air permeability and the thickness of the outer filter
layer. The air permeability is measured according to JIS LI096-A.
The thickness of the spacer layer must be between 0.7 mm and 3.5 mm. If the
thickness of the spacer layer is less than 0.7 mm, the flow of a body fluid become
extremely poor and the body fluid-treating filter device may become clogged. If the
thickness is more than 3.5 mm, on the other hand, flow of a body fluid becomes uneven
even if a flow passage resistant member is provided, increasing the amount of a body
fluid remaining in the body fluid-treating filter device when the body fluid is recovered
using a physiological solution. A more preferable range of the spacer thickness is from
0.9 mm to 2.5 mm, with a particularly preferable range being 1 mm to 2 mm.
In the case of a cylindrical body fluid-treating unit, the spacer layer is circular
and the thickness is 1/2 of the difference of the inner diameter and the outer diameter of
the ring. Specifically, the thickness of the outer spacer layer of the body fluid-treating
filter layer is 1/2 of the difference of the average outer diameter of the filter layer and
the average inner diameter of the cylindrical housing, and the thickness of the inner
13

spacer layer of the body fluid-treating filter layer is 1/2 of the difference of the average
outer diameter of the flow passage resistant member and the average inner diameter of
the body fluid-treating filter layer. When the filter layer is wound around the outside
of the spacer layer of a mesh material as described later in Examples, the thickness of
the inner spacer layer was determined from the difference of the average outer diameter
of the flow passage resistant member and the average inner diameter of the mesh layer.
Note that the thickness of the inner spacer layer is 0 mm when a spacer material is not
used, since the filter layer comes in contact with the outer surface of the flow passage
resistant member.
As mentioned above, if the thickness of the outer spacer layer is suitably
maintained and the pressure loss in the area near the body fluid flow port 51 (in this
case, a body fluid inlet port) of the body fluid-treating filter layer is increased by
providing a flow passage resistant member in the hollow section of the body
fluid-treating filter layer, as shown in Figure 8, for example, it is possible to control the
flow of a physiological saline solution in the area near the body fluid flow port 51 (inlet
port) of the inner spacer. As a result, the physiological saline solution sufficiently
flows to the area near the body fluid flow port 52 (in this case, a body fluid outlet port)
of the body fluid-treating filter layer, whereby sufficient blood recovery can be ensured.
The thickness of the arrows in Figure 8 qualitatively shows flowability of a body fluid,
that is, the flow rate magnitude.
The above structure not only reduces fluctuation of the blood flow in the body
fluid-treating filter layer during a blood treatment, but also prevents clogging and
suppresses a pressure loss due to an increased load at particular locations.
Seemingly, the structure of the device according to the present invention appears
to increase the pressure loss by providing a spacer layer. However, since the spacer
layer can offset a pressure increase due to an uneven flow, the overall pressure loss of
the device does not necessarily increase. In addition, the structure has an unexpected
14

advantage of preventing a rapid pressure increase.
Hereinafter, the present invention will be described in more detail by referring
to the examples. However, the present invention is not limited to them.
Example 1
(Preparation of cylindrical filter material)
The cylindrical filter layer used in Examples and Comparative Examples was
prepared by winding a spacer material used as an inner side spacer layer around a
rod-shaped member for assembly to be used as a core in the shape of a roll of cloth,
winding a spacer material to be used as an outer side spacer layer while controlling
torque to make the external diameter of the outer side spacer 38 mm, and extracting the
rod-shaped member.
First, polyethylene mesh (mesh size: 8, thickness: 0.75 mm, width: the same as
the housing length), which is the spacer material to be used as the inner side spacer layer,
was wound two rounds around the rod-shaped member to make the inner diameter 15
mm or more and the outer diameter 18 mm. Next, as a filter layer, the filter material
was directly wound around the rod-shaped member for assembly use (the inner side
spacer layer was not provided in Comparative Example 4). After that, the same
assembly procedure as above was followed.
From the inner side, 760 mm of nonwoven fabric (density: 98 g/m , thickness:
0.50 mm) made of polyester (PET, density: 1.38 g/cm ) fiber with an average diameter
of 2.7 micrometers was wound eleven rounds, 530 mm of nonwoven fabric (density:
102 g/m , thickness: 0.46 mm) made of polyester (PET, density: 1.38 g/cm ) fiber with
an average diameter of 12 micrometers was wound five rounds, 800 mm of nonwoven
fabric (density: 31 g/m , thickness: 0.19 mm) made of polyester (PET, density: 1.38
g/cm3) fiber with an average diameter of 12 micrometers was wound seven rounds, and
530 mm of nonwoven fabric (density: 50 g/m , thickness: 0.26 mm) made of polyester
(PET, density: 1.38 g/cm ) fiber with an average diameter of 33 micrometers was
15

wound 5 rounds. The width of each filter layer was the same as the length of the
housing which is described later. Lastly, polyethylene mesh (mesh size: 8, thickness:
0.75 mm, width: the same as the housing length) was wound one round as the outermost
spacer material.
(Assembly of filter device)
As a flow passage resistant member, a solid stick made of polycarbonate
(diameter; 15 mm, total length: 112.5 mm) was prepared. One end of the flow passage
resistant member was adhered with polyurethane to the center of a disk-like pan with an
inner diameter of 38 mm. The other end was inserted into a hollow section of the body
fluid-treating filter material, of which the end was liquid-tightly adhered with
polyurethane to the disk-like pan. On the other hand, the other end of the body
fluid-treating filter layer was liquid-tightly attached with polyurethane to a lid equipped
with a body fluid flow port, thereby connecting the hollow section of the filter layer
with the body fluid flow port. The resulting article was inserted in a cylinder (slightly
tapered, having dimensions of inner diameter (dl): 42 mm, inner diameter (d2): 41 mm,
inner diameter (d3): 42 mm, housing length: 150 mm, LI: 75 mm, average inner
diameter: 41.5 mm) made of polycarbonate, shown in Figure 9, and a lid equipped with
a body fluid flow port was liquid-tightly secured to the end of the housing using a
sealing cap. The other end of the cylinder was covered with a lid equipped with a
body fluid flow port and liquid-tightly secured to the end of the housing using a sealing
cap, thereby obtaining a body fluid-treating filter device shown in Figure 2.
Example 2
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except that a flow passage resistant
member with a diameter of 11 mm was used and polyethylene mesh, which is the spacer
material to be used as the inner side spacer layer, was wound four rounds to make the
inner diameter 11 mm or more and the outer diameter 18 mm.
16

Example 3
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except that a flow passage resistant
member with a diameter of 18 mm was used and polyethylene mesh (mesh size: 9,
thickness: 0.525 mm), which is the spacer material to be used as the inner side spacer
layer, was wound one round to make the inner diameter 18 mm or more and the outer
diameter 19.4 mm. In this example, in order to make the outer diameter of the outer
side spacer layer 38 mm, torque was more tightly controlled than in the filter layer and
the outer side spacer layer of the other examples and comparative examples.
Example 4
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except for using a flow passage
resistant member with a diameter of 15 mm and a total length of 18.75 mm and a
polycarbonate cylinder having dimensions of an inner diameter (dl): 41.2 mm, inner
diameter (d2) : 39.9 mm, inner diameter (d3): 39.4 mm, housing length: 75 mm, LI:
37.5 mm, and average inner diameter: 40.1 mm.
Example 5
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except for using a flow passage
resistant member with a diameter of 15 mm and a total length of 37.5 mm and a
polycarbonate cylinder having dimensions of an inner diameter (dl): 41.2 mm, inner
diameter (d2): 39.9 mm, inner diameter (d3): 39.4 mm, housing length: 75 mm, LI:
37.5 mm, and average inner diameter: 40.1 mm.
Example 6
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except for using a flow passage
resistant member with a diameter of 15 mm and a total length of 56.25 mm and a
17

polycarbonate cylinder having dimensions of an inner diameter (dl): 41.2 mm, inner
diameter (d2): 39.9 mm, inner diameter (d3): 39.4 mm, housing length: 75 mm, LI:
37.5 mm, and average inner diameter: 40.1 mm.
Example 7
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except for using a flow passage
resistant member with a diameter of 15 mm and a total length of 70.31 mm and a
polycarbonate cylinder having dimensions of an inner diameter (dl): 41.2 mm, inner
diameter (d2): 39.9 mm, inner diameter (d3): 39.4 mm, housing length: 75 mm, LI:
37.5 mm, and average inner diameter: 40.1 mm.
Comparative Example 1
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except that a flow passage resistant
member was not used and polyethylene mesh, which is the spacer material to be used as
the inner side spacer layer, was wound two rounds to make the outer diameter 18 mm.
Comparative Example 2
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except that a flow passage resistant
member was not used, polyethylene mesh, which is the spacer material to be used as the
inner side spacer layer, was wound two rounds to make the outer diameter 18 mm, and a
polycarbonate cylinder having dimensions of an inner diameter (dl): 42 mm, inner
diameter (d2): 41 mm, inner diameter (d3): 42 mm, housing length: 75 mm, LI: 17 mm,
and average inner diameter: 41.5 mm was used.
Comparative Example 3
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except that a flow passage resistant
member with a diameter of 10 mm was used and polyethylene mesh, which is the spacer
18

material to be used as the inner side spacer layer, was wound two rounds to make the
inner diameter 10 mm or more and the outer diameter 18 mm.
Comparative Example 4
A body fluid-treating filter device according to the specification of Example 1
was obtained in the same manner as in Example 1, except that a flow passage resistant
member with a diameter of 18 mm was used and the filter material was wound around
the rod-shaped member without using a spacer material which functions as an inner side
spacer layer.
The specifications of the body fluid-treating filter devices used for the above
Examples and Comparative Examples are shown in Tables 1 to 3. That is, various
types of cylinders (cylindrical housings) are shown in Table 1, various types of flow
passage resistant members are shown in Table 2, and types of housings, types of the
flow passage resistant member, spacer layer thickness, and the ratio of the length of the
flow passage resistant member to the length of the housing are shown in Table 3. The
flow passage resistant members shown in Table 2 are cylinders with a fixed
cross-sectional area in the length direction. A slash in Table 3 indicates that no flow
passage resistant member was used.
Since fibers having a circular cross-section are stacked up in the polyethylene
mesh material, the maximum thickness is equivalent to twice the fiber diameter and the
minimum thickness is equivalent to the fiber diameter. Accordingly, the average value
was regarded as the thickness. Specifically, the fiber diameter was 0.5 mm for a mesh
size 8 and 0.35 mm for a mesh size 9, and the thickness of the mesh was respectively
0.75 mm and 0.525 mm.
TABLE 1
Housing type A B C
Inner diameter dl (mm) 42 42 41.2
Inner diameter d2 (mm) 41 41 39.9
Inner diameter d3 (mm) 42 42 39.4
Housing length (mm) 150 75 75
LI (mm) 75 17 37.5
Average inner diameter (mm) 41.5 41.5 40.1
19

TABLE 2

Flow passage
reistant member 1-1 1-2 1-3 1-4 2-1 2-2 2-3 2-4
Diameter (mm) 15 11 18 10 15 15 15 15
Total length (mm) 112.5 112.5 112.5 112.5 18.75 37.5 56.25 70.31
TABLE 3

Example Comparative Example

1 2 3 4 5 6 7 1 2 3 4
Type of housing A A A C C C C A B A A
Type of flow passage
resistant member 1-1 1-2 1-3 2-1 2-2 2-3 2-4 1-4 1-3
Outer side spacer
layer thickness (mm) 2.25 2.25 2.25 1.55 1.55 1.55 1.55 2.25 2.25 2.25 2.25
Inner side spacer layer
thickness (mm) 1.5 3.5 0.7 1.5 1.5 1.5 1.5 4 0
Length of body
fluid-treating filter
(mm) 150 150 150 75 75 75 75 150 75 150 150
Length of flow
passage resistant
member/length of
body fluid-treating
filter 0.75 0.75 0.75 0.25 0.5 0.75 0.94 0.75 0.75
Next, the pressure increase and body fluid recovery performance of these body
fluid-treating filter devices were evaluated. Details of the evaluation method are
described below.

A blood circulation circuit was prepared by connecting a blood circuit equipped
with a pressure measurement line and a blood pump to body fluid flow ports (two points
of an inlet port side and an outlet port side) of a body fluid-treating filter device and
installing a one-day preservation whole blood pool of a cow (erythrocyte concentration:
63,600 to 81,000 cells/μl), to which an anticoagulant was added. The blood was
circulated through the circuit at a prescribed flow rate, while monitoring the pressure
difference of the internal pressure of the circuit at the inlet port side and the outlet port
side of the body fluid-treating filter device. The pressure difference at the time of
reaching a predetermined blood throughput was regarded as the treating pressure
20

increase value.
Taking the difference in the volume of the body fluid-treating filter devices into
consideration, 2,000 ml of blood was treated at a flow rate of 50 ml/min in the group
with a large capacity (Examples 1 to 3 and Comparative Examples 1,3, and 4) and
1,000 ml of blood was treated at a flow rate of 25 ml/min in the group with a smaller
capacity (Examples 4 to 7 and Comparative Example 2).
In this evaluation, the pressure increase was judged by whether or not the
treating pressure increase value reaches 100 mmHg or not under the above-mentioned
conditions. This is because hemolysis does not occur easily during extracorporeal
circulation or the like if the treating pressure is not more than 100 mmHg.
(Measurement of amount of recovered body fluid)
The same blood circulation circuit as used in the evaluation of the treating
pressure increase was prepared. Using this blood circulation circuit, (1) a prescribed
amount of a one-day preservation whole blood pool of a cow (erythrocyte
concentration: 63,600 to 81,000 cells/μl), to which an anticoagulant was added, was
circulated through a body fluid-treating filter device. Next, using this circuit as a
one-through circuit, (2) blood in the device and the circuit was collected using a
prescribed amount of a physiological saline solution, (3) blood remaining in the body
fluid-treating filter device was collected by washing the device using a prescribed
amount of a physiological saline solution, and, at the same time, (4) blood was further
collected using a prescribed amount of purified water. Then, (5) the amount of blood
contained in the liquid collected in (3) and (4) was calculated from the concentration of
hemoglobin (hereinafter referred to as "Hb") in the erythrocytes contained in the liquid
collected in (3) and (4). The total sum of the blood was regarded as the amount of
residual blood.
The flow rate in the operations (1) to (3) above was determined taking the
difference in the volume of the body fluid-treating filter devices into consideration.
21

That is, (1) during the blood circulation, 3,000 ml of blood was treated at a flow rate of
50 ml/min in the group with a large capacity (Examples 1 to 3 and Comparative
Examples 1, 3, and 4) and 1,500 ml of blood was treated at a flow rate of 25 ml/min in
the group with a smaller capacity (Examples 4 to 7 and Comparative Example 2), (2)
during the blood collection, 200 ml of a physiological saline solution was caused to
flow at a flow rate of 50 ml/min in the group with a large capacity (Examples 1 to 3 and
Comparative Examples 1,3, and 4) and 100 ml of a physiological saline solution was
caused to flow at a flow rate of 25 ml/min in the group with a smaller capacity
(Examples 4 to 7 and Comparative Example 2), and (3) during washing and collection,
400 ml of a physiological saline solution was caused to flow at a flow rate of 50 ml/min
in the group with a large capacity (Examples 1 to 3 and Comparative Examples 1,3, and
4) and 200 ml of a physiological saline solution was caused to flow at a flow rate of 25
ml/min in the group with a smaller capacity (Examples 4 to 7 and Comparative
Example 2). In the above operation (4), 1,000 ml of purified water was caused to flow
at a flow rate of 50 ml/min to recover the liquid irrespective of the capacity.
To determine the Hb concentration contained in the recovered liquids, the liquid
recovered in the above operation (3) was ten-fold diluted with purified water to
hemolyze erythrocytes to measure absorbance at 560 nm, and for the liquid recovered in
the above operation (4) the absorbance at 560 nm was measured using the liquid
recovered with purified water as is. A calibration curve was prepared using the
resulting values of absorbance, based on which the Hb concentration was estimated.
For preparing the calibration curve, samples of a two-fold dilution series, up to a
64-fold dilution sample, were prepared using a dilution liquid prepared by ten-fold
diluting the blood before treating with purified water to hemolyze erythrocytes. The
absorbance at 560 nm was measured for each of the diluted samples using an
absorbance meter ("Spectra Thermo" manufactured by TECAN) to prepare the
calibration curve. The Hb concentration in cow blood before treating was determined
22

by measuring Hb in a one-day preservation whole blood pool of a cow, to which an
anticoagulant was added, using a multi-item automatic blood cell analyzer ("SF-3000"
manufactured by Sysmex).
These measured values, the amount of recovered liquids in (3) and (4) were
applied to the following formula (1) to calculate the amount of residual blood for each
recovered liquid. The total sum was regarded as the residual blood amount of the body
fluid-treating filter device.
Residual blood amount (ml) =
Recovered washing liquid (ml) * Hb concentration of recovered washing liquid
(g/dl)/Hb concentration of blood before treating (g/dl) (1)
Body fluid recovery performance was evaluated using a body fluid-treating filter
device which does not use a flow passage resistant member as a control. That is, the
body fluid recovery performance of Examples 1 to 3 and Comparative Examples 3 and
4 was evaluated by the ratio of the residual blood amounts in these Examples and
Comparative Examples to the residual blood amount of Comparative Example 1, and
the body fluid recovery performance of Examples 4 to 7 was evaluated by the ratio of
the residual blood amounts in these Examples to the residual blood amount of
Comparative Example 2. When making comparison with Comparative Example 1 or
Comparative Example 2, in order to prevent the effects of dispersion according to
individual differences of blood, the same blood was treated at the same time in the
Examples and Comparative Examples which were compared with Comparative
Example 1 or Comparative Example 2.
The results of evaluation are shown in Tables 4-1 and 4-2.
23

TABLE 4-1

Example Comparative Example

1 2 3 3 4
Treating pressure increase (100 mmHg >) YES YES YES YES NO
Amount of residual blood [a] 51.71 45.75 40.47 64.26 56.60
Simultaneously measured amount of
residual blood of Comparative Example 1
[b] 63.55 50.42 50.42 57.87 50.78
Body fluid recovery performance [a/b] 0.81 0.91 0.80 1.11 1.11
TABLE 4-2

Example

4 5 6 7
Treating pressure increase (100 mmHg >) YES YES YES YES
Amount of residual blood [a] 48.81 47.74 45.76 47.09
Simultaneously measured amount of residual
blood of Comparative Example 2 [b'] 59.61 59.61 59.61 59.61
Body fluid recovery performance [a/b'] 0.82 0.80 0.77 0.79
The results of Examples 1 to 3 and Comparative Examples 1,3, and 4 indicate
that treating pressure easily increases in the case in which the inner side spacer layer is
not provided. The results of Examples 1 to 7 and Comparative Examples 1 and 2
indicate that no significant increase of the treating pressure that might induce a clinical
problem occurs and the body fluid recovery performance increases irrespective of the
differences in the length and cross-sectional shape of the housing, if the thickness of the
spacer layer is within a certain range. The results of Examples 1 and 3 and
Comparative Example 4 indicate that there is a lower limit to the thickness of the spacer,
and the results of Examples 1 and 2 and Comparative Example 3 indicate that there is
an upper limit to the thickness of the spacer.
In Examples 4 to 7 and Comparative Example 3, the ratio of the volume of the
flow passage resistant member to the hollow section increases in the order of Example 4,
Comparative Example 3, Example 5, Example 6, and Example 7. The amount of
residual blood, however, was large in Comparative Example 3, indicating that not only
the volume and length of the flow passage resistant member are important, but also the
thickness of the spacer layer must be within a specific range.
24

Although the above Examples and Comparative Examples were described
referring to a structure in which the body fluid flow port connected to the outer
circumference of the body fluid-treating filter layer is used as the inlet port and the body
fluid flow port connected to the inner circumference of the body fluid-treating filter
layer is used as the outlet port, the flow passage resistance remains the same when the
inlet port and the outlet port are reversed (when the body fluid flows in the reverse
direction). Accordingly, the same results are obtained irrespective of the flow
direction.
Although the effect of the thickness of a spacer layer was evaluated in the inner
side spacer layer between the flow passage resistant member and inner circumference of
the body fluid-treating filter layer, the same results will be obtained when evaluating in
the outer side spacer layer between the outer circumference of the flow passage resistant
member layer and the inner circumference of the housing. Since the thickness of the
outer side spacer layer is in a rage of 0.7 mm to 3.5 mm at all points, there is almost no
probability that the decrease in the pressure loss in the outer side spacer layer will affect
the flow of blood.
Although several embodiments of the present invention have been described in
detail, the present invention is not limited to the above-mentioned embodiments, various
changes and modifications of the design being possible within the scope of the claims.
For example, the specification may be changed to the extent that cells and the
like contained in a body fluid are not damaged. The treating pressure is generally
required not to exceed 100 mmHg due to problems such as hemolysis. It is important
to appropriately select the flow amount, the shape of the device, and the filter material,
because the treating pressure varies according to these conditions and materials. More
specifically, when the treating pressure increases due to the increase in the amount of
body fluid to be treated, the increase in the treating pressure can be controlled by
controlling an increase in the treating linear velocity in the filter layer by increasing the
25

length of the device, while maintaining the same cross-sectional shape as in the
embodiment of the present invention. Alternatively, the increase in the treating
pressure can be controlled by enlarging the filtration cross-sectional area, while using
the device with the same length.
It is also possible to adjust the entrapping performance or adsorption
performance of the filter material by replacing the filter material with another material
having a smaller resistance without changing the cross-sectional shape or the length of
the device, provided that in order to sufficiently fill the inside of the filter device with a
body fluid during body fluid-treating, it is necessary that the body fluid throughput is
larger than the volume of the space in the device including the volume of the voids in
the filter material.
The amount of the body fluid treated by the body fluid-treating filter device of
the present invention is typically from 300 to 3,000 ml, the flow rate is typically from
10 to 200 ml/min, and the priming volume of the body fluid-treating filter device is
typically from 10 to 500 ml.
INDUSTRIAL APPLICABILITY
The body fluid-treating filter device of the present invention is useful for
removing specific proteins, leukocytes, toxins, and the like contained in body fluids of
patients to be applied to an extracorporeal circulation blood purification therapy of
curing autoimmune diseases, such as systemic lupus erythematosus, chronic or
malignant articular rheumatism, multiple sclerosis, chronic ulcerative colitis, and
Crohn's disease, as well as other diseases such as sepsis, inflammatory bowel disease,
leukemia, and cancer, or for immunity control before an organ transplant operation.
26

CLAIMS
27
1. A cylindrical body fluid-treating filter device comprising a cylindrical housing
which has two body fluid flow ports and a body fluid-treating cylindrical filter layer
housed in the cylindrical housing, the cylindrical filter layer being disposed so as to
divide the inner space of the housing into two hollow sections by liquid-tightly sealing
the both ends and securing at least one end thereof to the inner wall of the housing, one
of the hollow sections of the housing divided by the cylindrical filter layer
communicating with the first body fluid flow port, and the other hollow section in the
housing divided by the cylindrical filter layer communicating with the second body
fluid flow port, wherein a rod-shaped flow passage resistant member extends through
the hollow section along the center axis formed by the cylindrical filter layer, and a
spacer layer for allowing a body fluid to flow with a thickness of not less than 0.7 mm,
but not more than 3.5 mm, is provided between the outer circumference of the
cylindrical filter layer and the housing, and between the inner peripheral surface of the
cylindrical filter layer and the flow passage resistant member.
2. The cylindrical body fluid-treating filter device according to claim 1, wherein
the spacer layer for flowing a body fluid with a thickness of not less than 0.7 mm, but
not more than 3.5 mm, provided between the inner peripheral surface of the cylindrical
filter layer and the flow passage resistant member extends 1/4 to 15/16 of the length of
the hollow section from one end of the cylindrical filter layer.
3. The cylindrical body fluid-treating filter device according to claim 1 or 2,
wherein the flow passage resistant member has a shape of which the cross-sectional area
is fixed on the side near the end of the cylindrical filter layer, but continuously or
intermittently decreases toward the other end.


A body fluid treating filter device capable of maintaining its treating pressure within a
clinically safe pressure range even if body fluid treatment is performed over a long
period and having excellent property for recovering a body fluid after the body fluid
treatment is completed. A body fluid treating cylindrical filter layer is stores in a
cylindrical container having two body fluid flow ports. The cylindrical filter layer is
disposed so that the inner space of a container can be divided into two parts by making
its both end parts fluid-tight and fixing at least one of these both end parts to the inner
wall surface of the container. One of the inner spaces of the container divided by the
cylindrical filter layer is allowed to communicate with the first body fluid flow port and the other of the inner spaces of the container divided by the cylindrical filter layer is allowed to communicate with the second body fluid flow port. The body fluid treating
cylindrical filter device is characterized in that a bar-like flow passage resistant member
extending along the center axis is installed in the hollow part of the cylindrical filter
layer, and a spacer layer for flowing the body fluid of 0.7 to 3.5 mm in thickness is
formed between the outer peripheral surface of the cylindrical filter layer and the
container and between the inner peripheral surface of the cylindrical filter layer and the
flow passage resistance member.

Documents:

04641-kolnp-2007-abstract.pdf

04641-kolnp-2007-claims.pdf

04641-kolnp-2007-correspondence others.pdf

04641-kolnp-2007-description complete.pdf

04641-kolnp-2007-drawings.pdf

04641-kolnp-2007-form 1.pdf

04641-kolnp-2007-form 2.pdf

04641-kolnp-2007-form 3.pdf

04641-kolnp-2007-form 5.pdf

04641-kolnp-2007-international publication.pdf

04641-kolnp-2007-international search report.pdf

04641-kolnp-2007-others.pdf

04641-kolnp-2007-pct priority document notification.pdf

04641-kolnp-2007-pct request form.pdf

4641-KOLNP-2007-(08-04-2013)-CORRESPONDENCE.pdf

4641-KOLNP-2007-(08-08-2014)-ANNEXURE TO FORM 3.pdf

4641-KOLNP-2007-(08-08-2014)-CORRESPONDENCE.pdf

4641-KOLNP-2007-(08-08-2014)-OTHERS.pdf

4641-KOLNP-2007-(21-05-2012)-CERTIFIED COPIES(OTHER COUNTRIES).pdf

4641-KOLNP-2007-(21-05-2012)-CORRESPONDENCE.pdf

4641-KOLNP-2007-(21-05-2012)-FORM-6.pdf

4641-KOLNP-2007-(21-05-2012)-PA.pdf

4641-KOLNP-2007-ABSTRACT 1.1.pdf

4641-KOLNP-2007-CANCELLED PAGES.pdf

4641-KOLNP-2007-CLAIMS 1.1.pdf

4641-KOLNP-2007-CORRESPONDENCE OTHERS 1.1.pdf

4641-KOLNP-2007-CORRESPONDENCE OTHERS 1.2.pdf

4641-KOLNP-2007-CORRESPONDENCE OTHERS 1.3.pdf

4641-KOLNP-2007-DESCRIPTION (COMPLETE) 1.1.pdf

4641-KOLNP-2007-DRAWINGS 1.1.pdf

4641-KOLNP-2007-FORM 1.1.1.pdf

4641-kolnp-2007-FORM 18.pdf

4641-KOLNP-2007-FORM 2.1.1.pdf

4641-KOLNP-2007-INTERNATIONAL EXM REPORT.pdf

4641-KOLNP-2007-OTHERS-1.1.pdf

4641-KOLNP-2007-OTHERS.pdf

4641-KOLNP-2007-PA.pdf

4641-KOLNP-2007-PETITION UNDER RULE 137.pdf

4641-KOLNP-2007-PRIORITY DOCUMENT.pdf

4641-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf

4641-KOLNP-2007-SCHEDULE.pdf

4641-KOLNP-2007-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf

abstract-04641-kolnp-2007.jpg


Patent Number 265099
Indian Patent Application Number 4641/KOLNP/2007
PG Journal Number 07/2015
Publication Date 13-Feb-2015
Grant Date 06-Feb-2015
Date of Filing 30-Nov-2007
Name of Patentee ASAHI KASEI MEDICAL CO., LIMITED
Applicant Address 1-105 KANDA JINBO-CHO, CHIYODA-KU, TOKYO., JAPAN., A JAPANESE COMPANY
Inventors:
# Inventor's Name Inventor's Address
1 TAKESHI, SUKEGAWA 1-2, YURAKU-CHO 1-CHOME, CHIYODA-KU, TOKYO 100-8440
2 YUKIHIKO, UCHI 1-2, YURAKU-CHO 1-CHOME, CHIYODA-KU, TOKYO 100-8440
PCT International Classification Number A61M 1/34, A61M 1/36
PCT International Application Number PCT/JP2006/310168
PCT International Filing date 2006-05-22
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 2005-149442 2005-05-23 Japan